Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas?

封面

如何引用文章

全文:

详细

Non-Hodgkin lymphomas are a heterogeneous group of hematological malignancies, the vast majority of which are B-cell tumors. Standard immunochemotherapy with anti-CD20 monoclonal antibodies is effective as the first-line therapy in treating these lymphoproliferative diseases. However, many patients develop a relapse or refractory disease. Recent therapeutic advances with new targeted agents and cell-based therapies have improved treatment outcomes. However, most of the new strategies cannot cure the disease or achieve long-term remissions, leaving a part of patients with an unmet need for effective and well-tolerated treatment options. One of the most promising therapeutic options is bispecific antibodies, which are expected to provide an unprecedentedly high level of deep responses with an improved safety profile. The available data open up prospects for extrapolating these results to the overall survival of patients.

作者简介

Irina Poddubnaya

Russian Medical Academy of Continuous Professional Education

编辑信件的主要联系方式.
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801

D. Sci. (Med.), Prof., Acad. RAS

俄罗斯联邦, Moscow

参考

  1. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42. doi: 10.1056/NEJMoa011795
  2. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 2023;41(2):154-62. doi: 10.1200/JCO.22.02403
  3. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-58. doi: 10.1056/NEJMra2027612
  4. Sarkozy C, Maurer MJ, Link BK, et al. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol. 2019;37(2):144-52. doi: 10.1200/JCO.18.00400
  5. Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307-15. doi: 10.1182/blood.2022018893
  6. Alencar AJ, Moskowitz CH. Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma. J Clin Oncol. 2021;39(5):467-75. doi: 10.1200/JCO.20.01751
  7. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. doi: 10.1182/blood-2017-03-769620
  8. Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51-7. doi: 10.1038/bmt.2015.213
  9. Перспективы применения биспецифических антител в третьей и последующих линиях терапии фолликулярной лимфомы (резолюция по итогам заседания совета экспертов). Клиническая онкогематология. 2023;16(2):227-8 [Perspectives for the use of bispecific antibodies in the third- and subsequent-line therapies of follicular lymphoma (resolution of expert panel). Clinical Оncohematology. 2023;16(2):227-8 (in Russian)]. doi: 10.21320/6nkr3a68
  10. Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2019;184(5):753-9. doi: 10.1111/bjh.15708
  11. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74. doi: 10.1038/s41408-020-00340-z
  12. Kanters S, Ball G, Kahl B, et al. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. BMC Cancer. 2023;23(1):74. doi: 10.1186/s12885-023-10546-6
  13. Ghione P, Palomba ML, Ghesquieres H, et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023;108(3):822-32. doi: 10.3324/haematol.2022.281421
  14. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-65. doi: 10.1016/S1470-2045(22)00335-7
  15. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220-31. doi: 10.1056/NEJMoa2206913
  16. Dickinson M, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in patients with relapsed/refractory (R/R) large b-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. Hematological Oncology. 2023;41(S2):144-6. doi: 10.1002/hon.3163_95
  17. Sehn LH, Bartlett NL, Matasar M, et al. Mosunetuzumab demonstrates durable responses in patients with relapsed/refractory follicular lymphoma and ≥2 prior therapies: updated analysis of a pivotal phase II study. Hematological Oncology. 41:122-5. doi: 10.1002/hon.3163_83

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Event-free survival from the start of anti-relapse therapy for diffuse large B-cell lymphoma in various refractory subgroups in the SCHOLAR-1 study (Kaplan-Meier curves) [7].

下载 (77KB)
索引源数据
3. Fig. 2. Progression-free survival by line of therapy in follicular lymphoma in the SCHOLAR-5 study (Kaplan-Meier curves) [13].

下载 (124KB)
索引源数据
4. Fig. 3. Event-free survival of patients with diffuse large B-cell lymphoma by the depth of response to anti-relapse therapy in the SCHOLAR-1 study (Kaplan-Meier curves). Adapted from [7].

下载 (68KB)
索引源数据
5. Fig. 4. BsAb mechanism of action: a – BsAb binds to CD20 on B-cells and CD3 on T-cells; b – T-cell induces the release of pro-inflammatory cytokines and B-cell lysis.

下载 (64KB)
索引源数据
6. Pfoto

下载 (17KB)
索引源数据

版权所有 © Consilium Medicum, 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 


##common.cookie##